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House mouse tissue samples from 30 populations in Germany, Switzerland and the Azores were 
analyzed for sequence changes in the gene VKORC1, which potentially confer resistance to 
anticoagulant rodenticides. Except for one population originating from south Germany, sequence variants 
were found in individuals from all locations analyzed (29 out of 30 sites surveyed), with less than 10 % 
of the individuals matching the wild-type genotype. The most frequent and widespread amino acid 
substitutions were Leu128Ser, Tyr139Cys and a group of linked sequence changes 
(Arg12Trp/Ala26Ser/Ala48Thr/Arg61Leu). These three genotypes occurred either alone or in 
combination with each other or with other less frequent sequence changes. Where they occurred as the 
sole variant, the proportion of homozygous animals was 72-83 %, suggesting a high selection pressure 
due to permanent pest control in these populations. 
An evaluation of published data revealed that the three frequent sequence changes found are associated 
with a substantial loss of rodenticide efficacy of first generation anticoagulants (e.g. warfarin, 
coumatetralyl) as well as the second generation compound bromadiolone and most probably also 
difenacoum. Further studies are required to investigate the effect on compounds of higher potency, in 
particular, where combinations of sequence changes occur in one individual. 
 
